Kbc Group Nv Cellectis S.A. Transaction History

Kbc Group Nv

$33.1 Billion
Q3 2024

A detailed history of Kbc Group Nv transactions in Cellectis S.A. stock. As of the latest transaction made, Kbc Group Nv holds 163,447 shares of CLLS stock, worth $294,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

163,447

Previous 163,447 -0.0%

Holding current value

$294,204

Previous $306,000 13.4%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	BUY	$11.94 - $16.09 $440,132 - $593,109	36,862 Added 29.12%	163,447 $2.06 Million
Q2 2021 Aug 11, 2021	BUY	$14.36 - $20.93 $655,778 - $955,810	45,667 Added 56.44%	126,585 $1.96 Million
Q1 2021 Apr 26, 2021	BUY	$18.19 - $33.25 $57,971 - $105,967	3,187 Added 4.1%	80,918 $1.64 Million
Q4 2020 Feb 10, 2021	BUY	$15.87 - $31.64 $470,529 - $938,094	29,649 Added 61.66%	77,731 $2.1 Million
Q3 2020 Oct 28, 2020	BUY	$15.7 - $20.84 $228,733 - $303,617	14,569 Added 43.47%	48,082 $890,000
Q2 2020 Aug 10, 2020	BUY	$8.21 - $21.02 $122,263 - $313,029	14,892 Added 79.97%	33,513 $597,000
Q1 2019 May 10, 2019	BUY	$15.53 - $19.75 $67,633 - $86,011	4,355 Added 30.53%	18,621 $0
Q4 2018 Jan 31, 2019	BUY	$15.58 - $28.41 $41,458 - $75,599	2,661 Added 22.93%	14,266 $237,000
Q1 2018 May 09, 2018	SELL	$27.78 - $35.19 $34,558 - $43,776	-1,244 Reduced 9.68%	11,605 $0
Q3 2017 Nov 13, 2017	BUY	$21.65 - $32.18 $278,180 - $413,480	12,849	12,849 $0

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.8M

Call Options Held

5.9K

Put Options Held

1.4K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $81.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account